EnduraFAST and LANL Partner for Enzyme Performance Advancements
News related to:EnduraFAST Inc. (dba Endurazymes) · 2 min read
EnduraFAST Inc., a biotechnology company specializing in improving the performance of enzymes under real-world operating conditions, has entered into an exclusive license agreement with Los Alamos National Laboratory (LANL). The agreement is aimed at providing EnduraFAST with the scientific foundation necessary to advance the commercialization of industrial biology, which is increasingly becoming an important manufacturing technology across various sectors including energy, agriculture, mining, environmental technologies, pharmaceuticals, and more.
The collaboration between EnduraFAST and LANL is designed to address a critical challenge in the field of enzyme development: how to identify and validate which enzymes are truly ready for real-world application. This challenge is particularly pertinent as biology plays an increasingly significant role in solving real-world challenges, and the success of promising scientific discoveries often hinges on their ability to perform effectively under the conditions for which they are intended.
LANL's licensed technology, developed to enable researchers to evaluate enzyme performance under relevant operating conditions, is now being leveraged by EnduraFAST to provide earlier insight into which enzyme candidates are most likely to succeed in commercial applications. This advancement in data generation and analysis is expected to significantly reduce uncertainty and the time required for enzyme development and commercialization, thereby enabling organizations to make more informed and confident decisions.
DeLuise's vision aligns with LANL's mission of advancing technology transfer and partnership development, which is key to moving promising research into tangible solutions.
The Laboratory's participation in this announcement is limited to factual statements regarding the technology and the licensing relationship, without any endorsement of EnduraFAST or its commercial products or services. This exclusive license agreement represents a significant step forward for EnduraFAST in its mission to improve confidence in enzyme performance, thereby accelerating the commercialization of industrial biology.
EnduraFAST's commitment to advancing industrial biology through better data on enzyme performance under real-world conditions underscores its position as a leader in the field. The company's collaboration with LANL is expected to further solidify its reputation and position in the industry, as well as contribute to the broader goal of leveraging biology as a manufacturing technology to address real-world challenges.
Los Alamos National Laboratory, known for its expertise in innovation and technology transfer, is playing a crucial role in this partnership by providing the scientific foundation that EnduraFAST needs to advance its commercial platform. The Laboratory's involvement not only supports EnduraFAST's mission but also contributes to the broader mission of advancing technology transfer and partnership development, ensuring that federally funded research transitions responsibly to industry and government partners.
As EnduraFAST continues to build on the scientific foundation provided by LANL, the company is poised to make significant contributions to the field of industrial biology, enabling faster and more confident decisions in commercialization. This collaboration exemplifies the potential for interdisciplinary collaboration to drive innovation and progress in critical areas such as industrial biology.